Author:
Maina Jane Wairimu,Mutua Jeniffer Munyiva,Musyoki Abednego Moki
Abstract
Abstract
Background
Carbapenem-resistant Gram-negative bacteria (CR-GNB) are a critical public health threat globally; however, there are inadequate surveillance data, especially in intensive care units (ICU), to inform infection prevention and control in many resource-constrained settings. Here, we assessed the prevalence of CR-GNB infections and risk factors for acquisition in a Kenyan ICU.
Methods
A hospital-based cross-sectional study design was adopted, recruiting 162 patients clinically presenting with bacterial infection after 48 h of ICU admission, from January to October 2022 at the Nairobi West Hospital, Kenya. Demographics and clinical data were collected by case report form. The type of sample collected, including blood, tracheal aspirate, ascitic tap, urine, stool, and sputum depended on the patient’s clinical presentation and were transported to the hospital Microbiology laboratory in a cool box for processing within 2 h. The samples were analyzed by cultured and BD Phoenix system used for isolates’ identity and antimicrobial susceptibility.
Results
CR-GNB infections prevalence was 25.9% (42/162), with Klebsiella pneumoniae (35.7%, 15/42) and Pseudomonas aeruginosa (26.2%, 11/42) predominating. All isolates were multidrug-resistant (MDR). P. aeruginosa and A. baumannii were 100% colistin-resistant, while K. pneumoniae (33.3%) was tigecycline-resistant. History of antibiotics (aOR = 3.40, p = 0.005) and nasogastric tube (NGT) use (aOR = 5.84, p = < 0.001) were the risk factors for infection.
Conclusion
Our study highlights high MDR- and CR-GNB infections in ICU, with prior antibiotic exposure and NGT use as risk factors, and diminishing clinical value of colistin and tigecycline. In this study setting and beyond, strict implementation of antimicrobial stewardship programs and adherence to infection prevention and control through monitoring, evaluation and feedback are warranted to curb CR-GNB infections, especially among the risk groups.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Jean S-S, Harnod D, Hsueh P-R. Global threat of Carbapenem-Resistant Gram-negative Bacteria. Front Cell Infect Microbiol. Mar. 2022;12:823684. https://doi.org/10.3389/fcimb.2022.823684.
2. WHO publishes list of bacteria for which new antibiotics are urgently needed. Accessed: Aug. 12. 2023. [Online]. Available: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.
3. An overview of the antimicrobial resistance mechanisms of bacteria - PMC. Accessed: Aug. 12, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604941/.
4. D. Y, Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol. 69, no. Suppl 7, Nov. 2019, https://doi.org/10.1093/cid/ciz830.
5. Blot S, et al. Healthcare-associated infections in adult intensive care unit patients: changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive Crit Care Nurs. Jun. 2022;70:103227. https://doi.org/10.1016/j.iccn.2022.103227.